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Mimivirus, the largest virus known to date, is an ame-
bal pathogen–like Legionella sp. When Mimivirus was used
as an antigen in a migration inhibition factor assay, sero-
conversion was found in patients with both community- and
hospital-acquired pneumonia. Mimivirus DNA was found in
respiratory samples of a patient with hospital-acquired
pneumonia.
T
he causative agent of pneumonia, the leading cause of
infection-related death throughout the world, is
unknown in 20% to 50% of cases (1). Therefore, identify-
ing new causative agents of both community- and hospital-
acquired pneumonia is a major public health goal. Aquatic
bacteria such as Legionella  spp., Pseudomonas  spp.,
Stenotrophomonas  spp., Burkholderia  spp., and
Acinetobacter spp. colonize hospital water supplies. These
bacteria, such as L. pneumophila, have been causally asso-
ciated with both hospital- and community-acquired pneu-
monia. Legionella spp. and other bacteria are associated
with free-living amebas in natural and hospital aquatic
environments (2). Bacteria that resist phagocytic destruc-
tion by amebas and are found in aerosolized water are
potential agents of pneumonia (3). Ameba-associated bac-
teria other than L. pneumophila, including other
Legionella spp., new α-proteobacteria belonging to the
Bradyrhizobiaceae (Bosea massiliensis) family, and mem-
bers of the genus Parachlamydia might be implicated in
hospital-acquired pneumonia (4–6). 
In strict intraamebal bacteria, we found Legionella-like
amebal pathogens (7), Parachlamydia acanthamebae (8),
and a giant virus resembling gram-positive cocci that we
named Mimivirus (9). The Mimivirus’s genome is larger
than that of Mycoplasma and genome sequencing is fin-
ished (10). Because we found antibodies against several
ameba-associated bacteria in patients with community-
and hospital-acquired pneumonia (3,4) in previous studies,
we tested for antibodies to Mimivirus by using a microim-
munofluorescence assay on serum samples from patients
with community- and hospital-acquired pneumonia. DNA
of Mimivirus was also found in the bronchoalveolar lavage
specimens of patients with hospital-acquired pneumonia.
The Study
We studied serum samples from 376 Canadian patients
with community-acquired pneumonia (121 ambulatory and
255 hospitalized) and from 511 healthy control subjects.
Extensive clinical data were available for 104 patients with
community-acquired pneumonia. All of these samples were
previously tested for other pneumonia agents (4). To pre-
pare antigen for microimmunofluorescence study,
Mimivirus was grown in Acanthameba polyphaga strain
Linc AP-1 in 75-cm2 cell culture flasks with peptone yeast
extract glucose medium as previously described (11). After
amebal lysis occurred, unlysed amebas were removed by
low speed centrifugation at 100 g for 15 min. Mimivirus
particles present in supernatant were centrifuged at 4,000 g
for 30 min and washed 3 times in phosphate-buffered saline
(PBS). The pellet obtained after the last washing was then
resuspended in PBS at 2 mg/mL concentration of protein
and used as antigen in microimmunofluorescence assay
under previously described conditions (5). Evidence of
serologic reaction to Mimivirus was defined as: 1) serocon-
version from <1:50 to >1:100 between acute-phase and
convalescent-phase serum samples or a 4-fold rise in anti-
body titer between acute-phase and convalescent-phase
serum samples, or 2) a single or stable titer of >1:400. The
cut-off titer for single serum was chosen to have <2.5%
positive rate in control subjects. We also tested paired
serum samples from 26 patients with intensive care unit
(ICU)-acquired pneumonia for a 1-year period and 50
paired serum samples from patients in our institution to
determine antibodies to Rickettsia spp. as controls. 
To verify that antibodies against Mimivirus in patients
with pneumonia recognize Mimivirus particles specifically,
a serum sample of 1 of these patients was used to detect
Mimivirus particles by immunogold technique as previous-
ly described (12). Two serum samples of patients who did
not have detectable antibodies against Mimivirus were used
as controls. Grids were incubated briefly twice in incuba-
tion buffer (PBS with 0.2% bovine serum albumin) for 5
min, then for 15 min in lysine buffer (PBS with 0.05 mol
lysin). Grids were washed twice in incubation buffer for 5
min, then incubated for 3 h at 37°C in patients’diluted sam-
ples (diluted 1/1,000 in incubation buffer with 3% nonfat
dry milk). Grids were washed 6 times for 5 min in incuba-
tion buffer, then incubated for 2 h at 37°C in goat antihuman
immunoglobulin (IgG)-gold conjugate (Aurion Biovalley,
Marne la Vallee, France) diluted 1/20 in incubation buffer
with 3% nonfat dry milk. Grids were washed 6 times for 5
min in incubation buffer, then twice in PBS for 5 min. Grids
were then immersed twice in gutaraldehyde (2% in PBS)
for 5 min, rinsed 3 times in distilled water for 5 min, treat-
ed by R-GENT SE-EM (Aurion Biovalley) for 25 min, then
rinsed 3 times in distilled water for 5 min before being
stained with uranyl acetate before examination.
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Mimivirus was found in bronchoalveolar lavage speci-
mens from 1 of 32 patients with ICU-acquired pneumonia
and none in specimens from 21 intubated control patients
in ICU who did not have pneumonia (5). We designed 4
primer pairs chosen from the genome sequence of
Mimivirus. To avoid any contamination, we used a nested
polymerase chain reaction (PCR), previously described as
“suicide-PCR,” that incorporates 2 primer pairs used only
once without positive control, followed by sequencing and
comparing to the targeted sequence (13). DNA from
patient and control BAL specimens, 3 water samples, and
a suspension of A. polyphaga were extracted by using the
QIAmp Tissue kit (QIAGEN GmbH, Hilden, Germany).
DNA extracts from selected pathogens, including agents
that are most commonly encountered in cases of hospital-
acquired pneumonia (14), were tested: Enterobacter aero-
genes, Proteus mirabilis, Citrobacter freundii, Escherichia
coli,  Citrobacter koseri,  Klebsiella pneumoniae,
Enterobacter cloacae, Serratia marcescens, Haemophilus
influenzae,  Moraxella catarrhalis,  Acinetobacter bau-
manii,  Stenotrophomonas maltophila,  Pseudomonas
aeruginosa,  Bacteroides fragilis,  Prevotella intermedia,
Streptococcus pneumoniae,  Streptococcus oralis,
Staphylococcus aureus,  Staphylococcus epidermidis,
Candida albicans, CMV, HSV1, and adenovirus.
Extracted DNA was used as template with primers BCFE
(5′-TTATTGGTCCCAATGCTACTC-3′) and BCRE (5′-
TAATTACCATACGCAATTCCTG-3′) as external primers
and BCFI (5′-TGTCATTCCAAATGTTAACGAAAC-3′)
and BCRI (5′-GCCATAGCATTTAGTCCGAAAG-3′) as
internal primers. A minimum of 1 negative control was
used for every 2 samples from patients with pneumonia;
testing was conducted in a blinded manner.
Conclusions
In the study of 511 healthy Canadian controls, 12
(2.3%) exhibited a substantial titer of antibodies to
Mimivirus. Patients with community-acquired pneumonia
were positive more frequently than controls, as 36 (9.66%)
were found positive (chi-square test, p < 0.01). Although
the typical morphologic traits of Mimivirus make its con-
fusion with ameba organelles unlikely (Figure), positive
serum samples tested on noninfected intact amebas sus-
pended in PBS by using the same migration inhibition fac-
tor protocol did not show any reactivity. Immunoelectron
microscopic examination showed that antibodies of posi-
tive patients recognize mature Mimivirus particles specifi-
cally (Figure), whereas antibody fixation was not found in
serum samples from 2 patients who were negative for
Mimivirus (data not shown). We compared selected fea-
tures of 14 patients with community-acquired pneumonia
who had serologic evidence of infection with Mimivirus
with those of 90 patients with community-acquired pneu-
monia who were seronegative for Mimivirus (Table). Only
hospitalization from a nursing home (3/14 vs. 3/90) and
rehospitalization after discharge (6/14 vs. 16/90) were sig-
nificantly associated with Mimivirus antibodies (p < 0.05).
Older age and diabetes mellitus were more common (both
6/14 versus 18/90) in patients with Mimivirus antibodies
but not significantly so (p = 0.07). In patients with commu-
nity-acquired pneumonia, more frequent rehospitalization
after discharge in patients with serologic evidence of
Mimivirus is likely explained by the poor efficacy of
antimicrobial agents against viruses (15). Seropositive
patients with community-acquired pneumonia were more
likely to be admitted from a nursing home; this factor sug-
gests that Mimivirus is a particularly good candidate as an
etiologic agent of pneumonia acquired in institutions, as is
L. pneumophila (16). The seroprevalence of Mimivirus
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Figure. As observed by scanning electronic microscopy,
Mimivirus antigen (A) is recognized by antibodies in our microim-
munofluorescence assay using conventional fluorescence micro-
scope (B) and confocal microscope (C). Mature particles within
amebas are also recognized by antibodies seen with transmission
electronic microscopy immunogold technique (D) (Mimivirus par-
ticle size 400 nm).was significantly higher than that of ameba–associated
bacteria tested on the same samples (4).
Serologic evidence of infection was observed in 5
(19.2%) of 26 ICU patients. None of the 50 control
patients was positive for Mimivirus (p < 0.01). Mimivirus
DNA was detected in bronchoalveolar lavage specimen
from a 60-year-old comatose patient who had 2 episodes of
hospital-acquired pneumonia during hospitalization in
ICU. Mimivirus DNA was amplified from the second
episode sample only. The sequenced amplified fragment
was 100% homologous to the target DNA (GenBank
accession no. AY026860). No serum sample was available
from this patient. None of the DNA extracts from control
microorganism showed a positive PCR reaction. The find-
ing of Mimivirus DNAin the bronchoalveolar lavage spec-
imens from an ICU patient with nosocomial pneumonia
confirms that Mimivirus may reach the respiratory tract of
these patients. Because of the procedure used for suicide
PCR amplification, contamination appears highly unlikely.
In this patient, however, we cannot distinguish coloniza-
tion and infection, but this feature is common to most
microorganisms isolated from respiratory samples.
This high rate of seroconversion observed in patients
with pneumonia from our seroepidemiologic study sug-
gests that community-acquired pneumonia and hospital-
acquired pneumonia patients may have contact with
Mimivirus or a cross-reacting agent. As we do not report
direct evidence of infection by Mimivirus, these results
have to be interpreted with caution. Viruses usually have a
broad range of hosts, but the extraordinary size of the
Mimivirus genome (1.2 Mb), comparable to that of small
bacteria such as Mycoplasma  (17), suggests a possible
adaptation to an extended range of hosts. We propose that
Mimivirus be tested as a possible novel human pathogen
among ameba-resisting microorganisms. These results are
preliminary, but raise the question of the pathogenic poten-
tial of the biggest identified virus to date. Mimivirus is an
agent easy to cultivate and is freely available from our lab-
oratory on request to researchers working on pneumonia
who wish to introduce Mimivirus antigen in serologic tests
to confirm our results.
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